Intuitive Surgical Inc. (ISRG) saw its stock decline 6.6% on Monday, closing at $420.22 after touching a 52-week low of $417.80. The drop came as the U.S. Food and Drug Administration (FDA) designated a recall of the company's SureForm 30 Gray Reloads as a Class I event, the most serious classification, linked to four major injuries and one death. The broader iShares U.S. Medical Devices ETF also fell about 3% on the day.
FDA Recall Details
The FDA's enforcement report indicates that Intuitive initiated the recall on March 11, but it remains ongoing. The affected products are 8mm SureForm 30 Gray Reloads designed for curved-tip staplers, with the agency noting incomplete staple lines affecting blood vessels. The company is still investigating the root cause, and impacted items were distributed across the U.S. and internationally.
Strong Q1 Results Overshadowed
Despite the safety concerns, Intuitive reported robust first-quarter results. Revenue climbed 23% year-over-year to $2.77 billion, while da Vinci procedure volumes rose approximately 16%. Adjusted earnings per share (non-GAAP) came in at $2.50, excluding stock-based compensation, acquisition-related expenses, and legal items. CEO Dave Rosa highlighted "expanded adoption" across the da Vinci, Ion, and digital platforms.
Tariff and Competitive Pressures
However, investors remain cautious about the company's outlook. Intuitive guided for da Vinci procedure growth of 13.5% to 15.5% in 2026, with adjusted gross margin guidance already incorporating a tariff impact of about 1% of revenue. The company warned that additional tariffs could materially affect 2026 results. Meanwhile, Johnson & Johnson (JNJ) advanced its rival OTTAVA surgical robot, reporting positive safety and performance data from a 30-patient gastric-bypass trial on May 5. Medtronic's (MDT) Hugo robotic platform is now in over 35 countries, with Cleveland Clinic performing the first U.S. commercial procedure in February.
Analyst Reactions
Analysts were mixed following the earnings report. Piper Sandler's Adam Maeder lowered his price target on Intuitive to $580 from $620 but maintained an Overweight rating, citing stronger-than-expected volume growth and system placements. Baird raised its target to $610 from $575 with an Outperform rating, while Stifel kept its Buy rating and $670 target, noting that procedure growth beat both its estimates and consensus.
Market Implications
The stock's decline reflects investor uncertainty over the recall's resolution, potential tariff escalation, and heightened competition from J&J and Medtronic. Any prolonged recall or hospital purchasing delays could pressure margins or slow procedure growth. Monday's session underscored that strong quarterly results alone were insufficient to alleviate these concerns, leaving ISRG shares at a 52-week low.
